A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

Study Purpose

This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM).The study will consist of two parts: dose escalation (Part 1) and dose expansion (Part 2).The dose escalation (Part 1) of the study will evaluate the safety and tolerability of FHND6091 using a dose escalation scheme to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). And the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of FHND6091 at two selected dose levels to characterize the safety, tolerability and efficacy of FHND6091. A total of 40 evaluable participants will be enrolled in the study. The participants receiving treatment in part 1 and part 2 may continue combination treatment for a total of up to 12 cycles. After 12 cycles of therapy, the participants will continue treatment until the occurrence of PD, intolerable AEs, consent withdrawal, death or end of study based on the judgement of investigator's assessment.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patients must give written informed consent.
  • - Male or female patients 18 years or older.
  • - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
  • - Life expectancy of at least 12 weeks.
  • - Patients with multiple myeloma who have relapsed or refractory, intolerance or refuse treatment following at least 3 regimens or lines of therapy that must include an IMID (lenalidomide or thalidomide), a proteasome inhibitor (bortezomib) , a CD38-targeted mAbs and corticosteroids.
Patients must have received transplant therapy or are not suitable for transplant.
  • - For Patients With Relapsed Refractory Multiple Myeloma must have measurable disease defined by at least 1 of the following 2 measurements: Serum M-protein ≥ 5 g/L, or Urine M-protein ≥ 200 mg/24 hours.
For patients with serum free light chain as measurable disease: Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio.
  • - Clinical laboratory values as specified below within 14 days before the first dose of study drug: 1.
Hemoglobin ≥ 75 g/L, Absolute neutrophil count ≥ 1.0 x 10E9/L and Platelet count ≥ 75 x 10E9/L without blood transfusion, EPO or G-CSF and other medical support for at least 14 days prior to receiving screening. 2. Total bilirubin levels ≤ 2 x ULN, AST (SGOT) and ALT (SGPT) ≤ 2 x ULN. 3. Calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute as calculated by Cockcroft-Gault method. 4. Corrected Serum Calcium ≤ ULN.
  • - For man and women of childbearing potential: agreement to remain abstinent or use contraception, during the treatment period (including treatment interruptions) and for at least 180 days after the last dose of FHND6091 was administered.
Women of childbearing potential should be negative by serum pregnancy test within 7 days prior dosing.

Exclusion Criteria:

  • - Documented allergy to proteasome inhibitor or ; - Patients with peripheral neuropathy ≥ Grade 2 or Grade 1 peripheral neuropathy with pain.
  • - Patients with diarrhea > Grade 1 (Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline).
  • - Patients received chemotherapy, radiation therapy, targeted therapy, immunotherapy or other systemic anticancer therapy within 14 days prior FHND6091 treatment.
  • - Patients received ixazomib treatment within 5 elimination half-life prior first dose of FHND6091 treatment.
  • - Patients received allogeneic stem cell transplantation or autologous stem cell transplant with 12 weeks before screening.
  • - Patients with symptomatic brain metastases, leptomeningeal metastases or, spinal cord compression or central nervous system (CNS) injuries/abnormalities based on investigator judgement.
  • - Evidence of severe or uncontrolled systemic diseases (eg, unstable or uncompensated respiratory, hepatic or renal disease), or receive major surgery.
  • - Patients with unstable hypertension after drug treatment (SBP ≥140 mmHg, DBP ≥90 mmHg ) or heart failure, myocardial ischemia or myocardial infarction, unstable angina, arrhythmia (The corrected QT interval (Fridericia formula) interval (QTcF) > 470 msec for females and > 450 msec for men in electrocardiogram (ECG)).
  • - Patients with active, or a history of immunodeficiency, including HIV positive or other acquired and congenital immunodeficiency diseases, or a history of solid organ transplant.
  • - Patients with a history of other serious underlying diseases, such as: a, history of a clear neurological or psychiatric disorder, including epilepsy or dementia.
b, HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody. c, presence of infection requiring systemic treatment.
  • - Systemic treatment with strong inhibitors of of CYP3A4 or strong CYP3A4 inducers within 5 elimination half-life prior first dose of FHND6091 treatment.
- Patients have not recovered (ie, ≤ Grade 1 toxicity by CTCAE 5.0) from the reversible effects of prior antineoplastic therapy (except for alopecia ) - Patients with other malignancy; - Treatment with any investigational products within 28 days before the first dose of study treatment

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05271682
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Jianqin Mi, M.D.
Principal Investigator Affiliation Ruijin Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Arms & Interventions

Arms

Experimental: Part 1: 0.4 mg

FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 1: 0.8 mg

FHND6091, 0.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 1: 1.4 mg

FHND6091, 1.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 1: 2.0 mg

FHND6091, 2.0 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 1: 2.8 mg

FHND6091, 2.8 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 1: 3.6 mg

FHND6091, 3.6 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 2: lower dose expansion

FHND6091, a lower dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Experimental: Part 2: MTD pr MTD-1 dose expansion

FHND6091, MTD or MTD-1 dose, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period

Interventions

Drug: - FHND6091

FHND6091 capsules

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Bengbu, Anhui, China

Status

Not yet recruiting

Address

The first affiliated hospital of bengbu medical college

Bengbu, Anhui, 233000

Site Contact

Huan Zhou, Ph.D

shangmh@ctfh.com.cn

13665527160

Henan Cancer Hospital, Zhengzhou, Henan, China

Status

Recruiting

Address

Henan Cancer Hospital

Zhengzhou, Henan, 450003

Site Contact

Yuefang Chen

hnszlyygcp@163.com

0371-65588007

Ruijin Hospital, Shanghai, China

Status

Recruiting

Address

Ruijin Hospital

Shanghai, , 200025

Site Contact

Meiwen Shu

iec2020@rjh.com.cn

021-34188900